GRGérard Reach

Gérard Reach

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gérard Reach has a total of 93 co-authors. Here are the top co-authors by number of shared publications:

  • Marc Bénard

    Sorbonne Paris Nord University, Inserm U1153, Inrae U1125, Cnam, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center—University of Paris (CRESS), 93017 Bobigny, France

    3 shared publications
  • Sandrine Péneau

    Université Sorbonne Paris Nord and Université Paris Cité, INSERM, INRAE, CNAM, Centre for Research in Epidemiology and StatisticS (CRESS), Nutritional Epidemiology Research Team (EREN), Bobigny, France

    3 shared publications
  • Serge Hercberg

    Université Sorbonne Paris Nord and Université Paris Cité, INSERM, INRAE, CNAM, Centre for Research in Epidemiology and StatisticS (CRESS), Nutritional Epidemiology Research Team (EREN) , 74 rue Marcel Cachin, 93017 Bobigny, Seine-Saint-Denis

    3 shared publications
  • Emmanuelle Kesse-Guyot

    Université Sorbonne Paris Nord and Université Paris Cité, INSERM, INRAE, CNAM, Centre for Research in Epidemiology and StatisticS (CRESS), Nutritional Epidemiology Research Team (EREN), Bobigny, France

    2 shared publications
  • Fabrice Etilé

    Paris School of Economics and INRA, UMR1393 PjSE, 48 Boulevard Jourdan, 75014, Paris, France

    2 shared publications
  • France Bellisle

    Consultant in Psychology of Food Intake Paris France

    2 shared publications

Latest Publications

  • Open Access

    Phenylketonuria as an Adherence Disease

    by Gérard Reach

    This narrative review explores a novel challenge to adherence in patients with phenylketonuria (PKU). Traditional barriers to maintaining the core of PKU therapy, which involves dietary restrictions, include limited palatability, high costs, difficult access to low-phenylalanine foods, time constraints, and social interference. We propose that adherence may also be hindered by elevated phenylalanine levels in nonadherent patients, leading to cognitive and executive function impairment that reduces their ability to adhere to the diet. Specifically, we hypothesize that the pathophysiological features of PKU create a vicious cycle that exacerbates adherence challenges to the phenylalanine-restricted diet. We therefore propose that PKU may be considered “an adherence disease”. The implications of this hypothesis are threefold: 1. Long-term dietary nonadherence is probable among individuals with PKU; 2. the disease itself contributes to the difficulty in adhering to dietary restrictions, potentially alleviating patient guilt; 3. while treatment options depend on individual factors such as disease severity, the most effective approach to mitigating the neurocognitive and psychosocial impacts of PKU is to replace or restore phenylalanine hydroxylase activity. Plain Language Summary: Phenylketonuria (PKU) is the most common genetic metabolic disorder. Its management requires adhering to a challenging diet that eliminates phenylalanine to prevent its accumulation in the brain, which can cause significant neurological deficits affecting the patient’s quality of life.This review focuses on long-term adherence to this diet, as part of a broader investigation into the mechanisms of nonadherence which represents a critical issue in medicine.In this article, we propose to consider PKU as an adherence disease—a unique case where the disease’s pathophysiology negatively impacts adherence through a vicious cycle, detailed in this review.This narrative review is the first to apply general adherence concepts from other diseases to PKU in an interdisciplinary manner.Finally, the concept of “adherence disease”—analogous to terms like heart disease— suggests that adherence is a beneficial function prone to failure that can be corrected by understanding its mechanisms.This investigation provides strong support for research in gene therapy for PKU.


  • Information for Readers

    by Gérard Reach, Philippe Jaury

  • Open Access

    How is Patient Adherence Possible? A Novel Mechanistic Model of Adherence Based on Humanities

    by Gérard Reach

    Patient non-adherence is a major contemporary medical issue because of its consequences in terms of frequency, morbidity and mortality, and health care costs. This article aims to propose a mechanistic model of adherence based on the tenet that non-adherence is the default option, as long-term adherence in chronic diseases requires sustained effort. The real question becomes, how is patient adherence possible? By focusing on adherent patients, the paper explains the mental mechanisms of adherence using concepts largely drawn from humanities, philosophy of mind, and behavioral economics and presents the findings of empirical studies supporting these hypotheses. The analysis first demonstrates the relationship between patient adherence and temporality and the influence of character traits. Further, it points out the importance of habit, which allows adherence to become non-intentional, thereby sparing patients’ cognitive efforts. Finally, it points out the importance of the quality of the interaction between the person with a chronic disease and the health professional. These features explain why adherence is a syndrome (the healthy adherer phenotype), separating people into those who are safe and those who are at risk of non-adherence, non-control of diabetes, and complications. The concepts presented in this article summarize 20 years of personal clinical and philosophical reflection on patient adherence. They are mainly illustrated by examples from diabetes care but can be applied to all chronic diseases. This novel model of adherence has major practical and ethical implications, explaining the importance of patient education and shared medical decision-making in chronic disease management.


  • Open Access

    Patients’ Perceived Importance of Medication and Adherence in Polypharmacy, a Quantitative, Cross-Sectional Study Using a Questionnaire Administered in Three Doctors’ Private Practices in France

    by Gérard Reach, Aurélie Calvez, Nanthara Sritharan, Marouane Boubaya, Vincent Lévy, Stéphanie Sidorkiewicz, May Fiani

    Background Among the determinants of nonadherence, polypharmacy (common in people with multiple pathologies and especially in elderly patients), plays a major role. Objective In patients who are subject to polypharmacy involving different classes of medications, the first aim is to assess the impact of medication importance given by patients on (i) medication adherence and (ii) the respective effect of intentionality and habit in medication importance and medication adherence. The second objective is to compare the importance given to medication and adherence in the different therapeutic classes. Patients and Methods Patients taking 5–10 different medications for at least 1 month were included in a cross-sectional survey in three private practices in one region in France. Results This study included 130 patients (59.2 % female) with 851 medications in total. The mean ± standard deviation (SD) age was 70.5 ± 12.2 years. The mean ± SD of medications taken was 6.9 ± 1.7. Treatment adherence had a strong positive correlation with the patient-perceived medication importance (p < 0.001). Counter-intuitively, taking a large number of medications (≥7) was associated with being fully adherent (p = 0.02). A high intentional nonadherence score was negatively associated with high medication importance (p = 0.003). Furthermore, patient-perceived medication importance was positively associated with taking treatment by habit (p = 0.03). Overall nonadherence more strongly correlated with unintentional nonadherence (p < 0.001) than with intentional nonadherence (p = 0.02). Compared to the antihypertensive class, a decrease in adherence by medication was observed in psychoanaleptics (p < 0.0001) and drugs used in diabetes class (p = 0.002), and a decrease in importance in lipid-modifying agents class (p = 0.001) and psychoanaleptics (p < 0.0001). Conclusion The perception of the importance of a medicine is associated with the place of intentionality and habit in patient adherence. Therefore, explaining the importance of a medicine should become an important part of patient education.


  • Phénoménologie d’une médecine humaine comme rencontre

    by Gérard Reach

    L’auteur propose un changement de paradigme en définissant une médecine humaine comme la rencontre entre deux personnes, êtres doués de pensée complexe et caractérisés par leur individualité Il oppose la parole aux chiffres qui caractérisent l’ère du numérique. Communiquer c’est quitter le monologue intérieur utilisant l’endophasie, – vue comme pro-logue – pour l’échange, l’expression de la pensée en mots qui nécessite une relation de confiance. Au fondement de l’éthique de la rencontre, la symétrie d’une conversation s’ajoute à l’asymétrie de la consultation.

  • Open Access

    An Unsafe/Safe Typology in People with Type 2 Diabetes: Bridging Patients’ Expectations, Personality Traits, Medication Adherence, and Clinical Outcomes

    by Gérard Reach, Laurent Benarbia, Pierre-Yves Benhamou, Brigitte Delemer, Séverine Dubois, Didier Gouet, Bruno Guerci, Nathalie Jeandidier, Karim Lachgar, Gilles Le Pape, et al.

    Background: Support programs are provided to people with diabetes to help them manage their disease. However, adherence to and persistence in support programs are often low, making it difficult to demonstrate their effectiveness. Aim: To identify the determinants of patients’ perceived interest in diabetes support programs because it may be a powerful determinant of effective participation in such programs. Patients and Methods: An online study conducted in April 2021 in metropolitan France on 600 people with diabetes recruited from a consumer panel. A 64-item psychosocial questionnaire including a question asking to evaluate the helpfulness of a support program was used. Univariate, multivariate, and multiple correspondence analyses were performed. Results: The existence of a typology, known as Unsafe/Safe, was discovered, in which patients with type 2 diabetes respond in two distinct ways. Type U (unsafe) patients, who believe that a support program would be helpful, are more likely to be nonadherent to their treatment, have high hemoglobin A1c levels, have at least one diabetic complication, lack information regarding their disease and treatment, rate the burden of their disease and impairment of their quality of life as high, worry about their future, and are pessimistic. Type S (safe) patients have the opposite characteristics. Type U patients can be dichotomized into two broad classes: one in which they lack information regarding disease and treatment and the other in which alterations in the quality of life and burden of the disease predominate. Insulin-treated patients give more importance to the lack of information, whereas noninsulin-treated patients complain primarily about the burden of the disease and impairment of quality of life. Conclusion: This study describes this new U/S typology, proposes a simple method based on a nine-item questionnaire to identify type U patients by calculating a Program Helpfulness Score described herein, and clarifies the nature of the intervention to be provided to them. This novel approach could be applied to other chronic diseases.


  • Open Access

    Finalization and Validation of Questionnaire and Algorithm of SPUR, a New Adherence Profiling Tool

    by Elodie de Bock, Kevin Dolgin, Léa Kombargi, Benoit Arnould, Tanguy Vilcot, Guillaume Hubert, Marie-Eve Laporte, Lydiane Nabec, Gérard Reach

    Purpose: The SPUR (Social, Psychological, Usage and Rational) Adherence Profiling Tool is a recently developed adaptive instrument for assessing key patient-level drivers for non-adherence. This study describes the SPUR questionnaire’s finalization and psychometric evaluation. Patients and Methods: Data were collected through an online survey among patients with type 2 diabetes included by general practitioners and diabetologists in France. The survey included four questionnaires, SPUR and three validated adherence measures: BMQ, MARS and ACCEPT. Item-level analysis and a partial credit model (PCM) were performed to refine the response option coding of SPUR items. The final item selection of SPUR was defined using a PCM and a principal component analysis (PCA). Construct validity, concurrent validity and known-groups validity were assessed on the final SPUR questionnaire. Results: A total of 245 patients (55% men, mean age of 63 years) completed the survey remotely and were included in this analysis. Refining response option coding allowed a better discrimination of patients on the latent trait. After item selection, a short, an intermediate, and a long form composed the final SPUR questionnaire. The short form will be used to screen patients for risk and then the other forms will allow the collection of further information to refine the risk assessment and decide the best levers for action. Results obtained were supportive of the construct validity of the forms. Their concurrent validity was demonstrated: moderate to high significant correlations were obtained with BMQ, MARS and ACCEPT scores. Their known-groups validity were shown with a logical pattern of higher scores obtained for patients considered non-adherent and significant differences between the scores obtained for patients considered adherent versus non-adherent. Conclusion: SPUR is a valid tool to evaluate the risk of non-adherence of patients, allowing effective intervention by providing insights into the respective individual reasons for lack of adherence.


  • Open Access

    Intentionality in adherence to long-term therapies. Results from an online survey of 3,001 patients with cardio-metabolic pathologies in France

    by Gérard Reach, Laurent Benarbia, Eric Bruckert, Jean-Philippe Kevorkian, Michel Farnier, Jean-Jacques Mourad, Bernard-Charles Vaisse

    Purpose: Some patients make a rational choice not to follow medical prescriptions; others fail to take their medications for reasons beyond their control, such as mere forgetfulness or a weak medication routine. The aim of this study was to elucidate the functioning of patient intentionality in medication adherence. Patients and Methods: This online study was conducted in metropolitan France in 2019. A cross-sectional survey of 50 questions was conducted with 3001 respondents diagnosed with diabetes, hypertension, and/or hypercholesterolemia identified from a panel of 54,000 people. These questions included a validated six-item questionnaire to detect nonadherence, two questions to detect intentional nonadherence by patients, and three questions on the effects of habit. Our questionnaire also included questions on the feelings of respondents regarding their doctor’s attitude to their problems and needs, their trust in general practitioners (GP) and specialists, their sense of being involved in treatment decisions, and the influence of side effects and habits on patients’ adherence. This study used the strategy of focusing on strictly adherent patients in the hope of finding ways to improve adherence. For this reason, we defined adherence as the absence of a positive response to the 6-item nonadherence screening questionnaire. Results: Of 3001 respondents, 1804 were diagnosed with hypertension, 1458 with hypercholesterolemia, and 774 with diabetes. Of the total number of patients, 72% were afflicted with one disease, 21% with two ailments, and 7% with three simultaneous illnesses. One-third (33%) of the patients did not tender a positive answer to the adherence questionnaire and were deemed adherent. 1) Thirty-two percent of the patients reported occasionally omitting their medication deliberately, and 84% said they had a reason for missing doses. These statements suggesting intentional nonadherence were negatively associated with adherence as identified via multivariate analysis (P = 0.0012 and P < 0.0001, for the first and second statement, respectively). 2) Univariate analyses revealed strong associations (P < 0.0001) between strict adherence on one hand and lack of intentional nonadherence, patient age, absence of drug side effects, taking drugs by habit, feeling involved in treatment decisions, getting information about treatment, and disease, and trust in doctors, on the other hand. 3) Specifically, univariate analysis of the absence of reported side effects revealed strong associations (P < 0.0001) with adequate information about medicines and diseases and trust in GP. These original data were consistent with the concept of the nocebo effect. 4) We observed a strong association between the absence of intentional nonadherence (statement of never deliberately missing medication) and respondent statements about generally sticking to the routine (P < 0.0001), ie, “I take my medication because I am used to taking it.” This important result suggests that patients are strictly adherent in two ways: the absence of intentional nonadherence and reliance on habit, which we term as “unintentional adherence.” 5) Finally, a multiple correspondence analysis illustrated all statistically significant relationships found in this study. Conclusion: We present a new global model of adherence in which patient adherence was improved both by reducing intentional nonadherence and by promoting the abovementioned unintentional adherence by habit. This model highlights the role of shared decision-making and the trust felt by patients in their doctors. These results could exert a major impact on medical practice and education by demonstrating the importance of physicians’ attitudes, involving the patient in decisions (shared decision-making), offering information about medicines and diseases (patient education), understanding the problems of patients, and taking their needs into account (empathy). The development of these attitudes should be an important aspect of the medical curricula.